The consultation is the part nobody prepares for

The drugs work on appetite, not on willpower, and they do it by imitating a hormone the gut releases after eating. GLP-1 — glucagon-like peptide-1 — slows how fast the stomach empties and acts on the parts of the brain that register fullness, which is why people describe the effect less as resisting food than as losing interest in it. That mechanism is the reason the medication is taken continuously rather than in a course, and it is also the reason the most consequential questions in a first consultation are not about whether the drug works. Whether it works is the settled part. What happens around it is not.

A first appointment for a GLP-1 prescription is often very short, and the shape of it tends to be driven by the prescriber's own risk checklist: contraindications, a few history questions, a starting dose, a date to come back. That is not negligence; it is triage, and it covers the things most likely to cause immediate harm. But a prescription of this kind is a long-term arrangement with a dosing schedule, a supply chain and an exit problem, and almost none of that is legally required to be discussed before the first injection. The gap between what a consultation must cover and what a person actually needs to know is where most of the difficulty lives.

What follows is the set of questions worth arriving with, and why each one matters. They are deliberately unglamorous. The interesting parts of this medication have been covered exhaustively; the parts that determine whether a year on it goes well are mostly logistics.

What is this specific drug, at this specific dose, expected to do?

Several drugs sit under the GLP-1 heading and they are not interchangeable. Some act on GLP-1 alone; newer ones act on more than one gut hormone receptor. They differ in dosing frequency, in the size of the average effect in trials, in side-effect profile and in what they are licensed for — which in some cases is diabetes and in others is weight management, and the distinction affects both supply and, in many systems, who pays.

So the question is not "does this work" but "which molecule am I being prescribed, at what dose, on what schedule, and what is the expected trajectory of that dose over the next six months". Almost every one of these drugs starts low and escalates on a fixed ladder, because starting at a therapeutic dose produces nausea severe enough that people stop. Knowing the ladder in advance changes how the first weeks are interpreted: a low starting dose that does little is the schedule working, not the drug failing.

What are the side effects likely to be, and which ones mean stop?

Gastrointestinal effects are the common ones and they are well documented: nausea, vomiting, constipation, diarrhoea, reflux. They cluster around dose increases and tend to settle, and much of the practical management is ordinary — smaller meals, eating slowly, stopping when full rather than when the plate is empty, which is harder to relearn than it sounds. A prescriber should say plainly which effects are expected and self-limiting, which warrant a call, and which warrant stopping the drug and being seen the same day. Severe persistent abdominal pain belongs in that last category. So does anything that suggests dehydration serious enough to affect the kidneys, which is a real risk when vomiting is prolonged and easy to underestimate because it arrives gradually.

The honest answer to "will I get side effects" is that the distribution is wide and there is no reliable way to predict where an individual sits in it before starting. A prescriber who promises you will be fine is going past the evidence.

What happens to muscle, and what is being done about it?

Weight lost on any substantial energy deficit is not only fat, and GLP-1 medication produces a substantial deficit by suppressing appetite. The proportion of lean mass lost, how much it matters over decades, and whether resistance training and higher protein intake meaningfully change that proportion in people taking these drugs are all areas of active research rather than settled fact. What is uncontroversial is that appetite suppression makes it easy to eat very little of anything, protein included, and that this is one of the few parts of the process a person has direct control over.

The question to ask, then, is whether the prescriber has any plan for this beyond mentioning it: a protein target, a referral, a conversation about strength work, anything. If the answer is no, that is worth knowing, because it tells you which parts of this you are managing yourself.

Who is monitoring me, how often, and what are they measuring?

This is the question most often skipped, particularly where the prescription comes through an online service. Monitoring should have a schedule and a content: what is checked, by whom, at what interval, and what would trigger a change. Weight is the least interesting measurement on the list. The useful ones are the things that tell you whether the drug is being tolerated and whether anything is going wrong quietly.

Ask who you contact between appointments, how quickly they respond, and what happens if you need to come off the dose ladder or pause. A service that can only escalate a dose is not really monitoring anything.

What does stopping look like?

This is the conversation to have on day one, and it is almost never had then. Because the drug works by suppressing appetite while it is in the body, appetite returns when it leaves, and the weight-regain trajectory after discontinuation has been documented in trial follow-ups. That is not a moral failure of the person or a scandal about the drug; it is what a drug that works on appetite does when it is no longer present. It does mean that starting is a decision with an open end.

People stop for reasons that have nothing to do with wanting to. Supply runs short. A price changes. Funding criteria shift. Side effects become intolerable. A pregnancy is planned, which requires stopping in advance rather than on discovery. Insurance ends with a job. So the questions are: is there a tapering approach or is this abrupt, what should be expected in the weeks after, what is the plan if the reason for stopping is cost rather than choice, and is there a maintenance dose lower than the top of the ladder that might be an option.

What will this cost in a year, not this month?

Introductory pricing is common in private weight-management services, and the price of a first month is a poor guide to the price of a twelfth, partly because dose escalation often means moving to a more expensive pen. Ask what each dose level costs, what happens to the price if you stay at a maintenance dose indefinitely, and what the consultation and monitoring fees are as distinct from the drug itself. Ask whether the service will keep prescribing if you decide not to increase the dose.

Compounded or unlicensed versions sold outside regulated pharmacy supply are a separate matter and carry a different risk profile, because the contents and the dosing instructions are not guaranteed to be what the label says.

If the consultation goes badly

Some of them do. The tell is not rudeness, which is obvious, but a consultation that treats your weight as the diagnosis and ends the inquiry there — a dose and a follow-up date, no history taken, no mention of monitoring or stopping, no room for a question. Weighing, if it happens, should be a measurement rather than a commentary, and the equipment should accommodate the person being weighed without a scene.

Practical responses, in rough order of effort:

• Ask for the specifics in writing — drug, dose schedule, monitoring interval, contact route for problems. A service that will not put it in writing has told you something.
• Ask directly what happens if you want to pause or come off, and note whether the answer is a plan or a shrug.
• Take somebody with you, or record the appointment if that is permitted where you are, because the recall problem after a short consultation is real.
• Ask to see a different prescriber. Requesting a second opinion within the same service is ordinary and does not require a justification.
• If the prescription came through an online questionnaire with no conversation at all, treat the monitoring question as unanswered until somebody answers it.

None of this resolves into a recommendation, because the decision depends on things only the person making it knows: what else is going on medically, what the money looks like over years rather than months, how much of the management they are willing to do themselves, and what they want to happen if the supply stops. The drugs are effective and the evidence on that is strong. The unsettled parts are mostly about duration, muscle, and what a decade on them looks like, because a decade has not happened yet. A prescriber who says that plainly is a good sign. What you do with it is yours.